A novel heparin-coated hydrophilic preparation of amphotericin B hydrosomes
- PMID: 11566003
A novel heparin-coated hydrophilic preparation of amphotericin B hydrosomes
Abstract
Amphotericin B Hydrosomes (AH; Access Pharmaceuticals Inc) are a novel formulation of hydrophilic, heparin-surfaced nanoparticles (mean diameter 105 nm) containing amphotericin B (AmB) designed to target infected sites by local adhesion. AH are cleared in part by a hepatobiliary mechanism, which results in a reduction of AmB concentration in major organs by about 50% in 24 h. In mice with pulmonary blastomycosis, unlike Fungizone (Bristol-Myers Squibb Inc), a deoxycholate micellar formulation of AmB, AH accumulates 3-fold more in infected lungs than normal lungs, between 3 and 24 h post-injection. Histologically, AH accumulates at the sites of lesions. AH is approximately 7-fold less toxic than Fungizone based on acute lethality and histopathological assessment of renal damage. In vitro, AH and Fungizone were equally active against Blastomyces dermatitidis and in vivo they were equivalent in prolonging mouse survival, when compared with equal dosing of AmB. In reducing infectious burdens in vivo, Fungizone was 3-fold more effective than AH on a mg/kg basis of administered AmB. However, AH at 4.8 mg/kg cured 50 to 60% of mice, whereas Fungizone at a near lethal dose of 1.2 mg/kg cured none. The AH formulation of AmB has an improved therapeutic index, relative renal-site avoidance and selective accumulation in infected tissues, which combine to merit additional studies in appropriate fungal models.
Similar articles
-
Amphotericin B-entrapping lipid nanoparticles and their in vitro and in vivo characteristics.Eur J Pharm Sci. 2009 Jun 28;37(3-4):313-20. doi: 10.1016/j.ejps.2009.02.021. Epub 2009 Mar 13. Eur J Pharm Sci. 2009. PMID: 19491021
-
Comparative study on the efficacy of AmBisome and Fungizone in a mouse model of pulmonary aspergillosis.J Antimicrob Chemother. 2006 Apr;57(4):724-31. doi: 10.1093/jac/dkl005. Epub 2006 Jan 30. J Antimicrob Chemother. 2006. PMID: 16446374
-
Efficacy of alternative dosing regimens of poly-aggregated amphotericin B.Int J Antimicrob Agents. 2008 Jul;32(1):55-61. doi: 10.1016/j.ijantimicag.2008.02.025. Epub 2008 Jun 4. Int J Antimicrob Agents. 2008. PMID: 18534826
-
Carrier effects on biological activity of amphotericin B.Clin Microbiol Rev. 1996 Oct;9(4):512-31. doi: 10.1128/CMR.9.4.512. Clin Microbiol Rev. 1996. PMID: 8894350 Free PMC article. Review.
-
Super aggregated form of Amphotericin B: a novel way to increase its therapeutic index.Curr Pharm Des. 2016;22(7):792-803. doi: 10.2174/1381612822666151209151719. Curr Pharm Des. 2016. PMID: 26648472 Review.
Cited by
-
Utilization of Glycosaminoglycans/Proteoglycans as Carriers for Targeted Therapy Delivery.Int J Cell Biol. 2015;2015:537560. doi: 10.1155/2015/537560. Epub 2015 Sep 10. Int J Cell Biol. 2015. PMID: 26448753 Free PMC article. Review.
-
Enhanced antifungal effects of amphotericin B-TPGS-b-(PCL-ran-PGA) nanoparticles in vitro and in vivo.Int J Nanomedicine. 2014 Nov 24;9:5403-13. doi: 10.2147/IJN.S71623. eCollection 2014. Int J Nanomedicine. 2014. PMID: 25473279 Free PMC article.
-
Animal models: an important tool in mycology.Med Mycol. 2007 Dec;45(8):657-84. doi: 10.1080/13693780701644140. Med Mycol. 2007. PMID: 18027253 Free PMC article. Review.
-
Optimizing efficacy of Amphotericin B through nanomodification.Int J Nanomedicine. 2007;2(3):301-13. Int J Nanomedicine. 2007. PMID: 18019830 Free PMC article. Review.